Sekkei Bio, an India-based company dedicated to building technologies for drug and vaccine design with global impact, has implemented CDD Vault as the main platform to house its research data.
Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team with a track record of successfully bringing drugs to market. The company has built an in-silico discovery engine based on this experience, which allows them to design and develop novel drugs and excipients.
The in-silico engine drives their in-house programmes and can also be accessed by other organisations through a range of flexible collaboration options. Sekkei Bio has also created an mRNA platform that provides a cost-effective and scalable solution for vaccines and therapeutics adapted to the regional need.
The implementation of CDD Vault will enable Sekkei Bio to store, manage and analyse their research data – including peptides, small molecules, and assay data – used to model the new drugs. The implementation of CDD Vault is key to the company’s collaborations as it enables data security right from query handling to library handover and allows for interactions with partners and collaborators in real time.
“Clean and organised data are the cornerstone of IP-able scientific progress. It is important to us to keep the traceability of the data and ensure that our data is secure yet readily accessible at the same time,” said Dr. Anirudh Ranganathan, Co-Founder of Sekkei Bio.
